Critical Review: Radiopharm Theranostics (NASDAQ:RADX) & Biodexa Pharmaceuticals (NASDAQ:BDRX)

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Biodexa Pharmaceuticals and Radiopharm Theranostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1	0	0	0	1.00
Radiopharm Theranostics	1	0	2	2	3.00

Radiopharm Theranostics has a consensus price target of $15.33, suggesting a potential upside of 213.57%. Given Radiopharm Theranostics’ stronger consensus rating and higher possible upside, analysts plainly believe Radiopharm Theranostics is more favorable than Biodexa Pharmaceuticals.

Profitability

This table compares Biodexa Pharmaceuticals and Radiopharm Theranostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Radiopharm Theranostics	N/A	N/A	N/A

Insider & Institutional Ownership

17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Biodexa Pharmaceuticals and Radiopharm Theranostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470,000.00	1.25	-$7.32 million	N/A	N/A
Radiopharm Theranostics	$2.35 million	24.57	-$24.83 million	N/A	N/A

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Radiopharm Theranostics.

Summary

Radiopharm Theranostics beats Biodexa Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.